CoChat

The Glp-1 Analog Liraglutide Protects Against Angiotensin II and Pressure Overload-Induced Cardiac Hypertrophy via PI3K/Akt1 and AMPKa Signaling

Open access
Li, Ran, Shan, Yingguang, Gao, Lu, Wang, Xi, Wang, Xule, Wang, Fang · 2019 · Frontiers in Pharmacology
Cited by 46

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Glp-1 analog, liraglutide (Lir), have been shown to reduce infarct size and improve cardiac function after myocardial ischaemia in rodents with or without diabetes. But the effect of Lri on angiotensin II (AngII) and pressure overload induced cardiac remodelling in non-diabetic mice and the underlying mechanism is unclear. The aim of this study is to investigate the effect of Lir on cardiac remodeling induced by AngII infusion, and explore its possible mechanism. Mice subjected to Angiotensin II as well as thoracic aorta coarctation to induce cardiac remodelling model. Mice were daily injected with either liraglutide or saline for 2 weeks. Neonatal rat cardiomyocytes and human AC cell lines were stimulated with AngII to induced cardiomyocytes remodelling model. Both in vivo and in vitro experiments indicated Lir significantly inhibited cardiac hypertrophy and improved cardiac function through directly suppressing the activation of PI3K/Akt1 and stimulating AMPKα signaling pathways. Moreover, mTOR activator (MHY1485), overexpression of constitutively active Akt, and knockdown of AMPKa2 expression all can abolish the protective effects of Lri. Moreover, the protective effects of Lri in vivo was lost in AMPKa2 knockout mice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2019.00537

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 46

Metadata

Authors
Li, R., Shan, Y., Gao, L., Wang, X., Wang, X., & Wang, F.
Venue
Frontiers in Pharmacology
Published
2019-06-05
Volume
10
Pages
537-537
ISSN
1663-9812 (ISSN-L)
OpenAlex
W2969696158
Cited by
46
References
5
FWCI
2.61
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.